Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong KongLimited take no responsibility for the contents of this announcement, make no representationas to its accuracy or completeness and expressly disclaim any liability whatsoever for anyloss howsoever arising from or in reliance upon the whole or any part of the contents of thisannouncement.
(incorporated in the Cayman Islands with limited liability)
Reference is made to the announcement of the Company dated 18 February 2013(‘‘Announcement’’). Capitalised terms used in this announcement shall have the samemeaning as those defined in the Announcement.
As set out in the Announcement, (1) for the purpose of determining the entitlement to attendand vote at the AGM, the register of members of the Company was scheduled to be closedfrom Thursday, 28 March 2013 to Wednesday, 3 April 2013, both dates inclusive; (2) forthe purpose of determining the entitlement to the proposed Final Dividend, the register ofmembers of the Company was scheduled to be closed from Wednesday, 17 April 2013 toFriday, 19 April 2013, both dates inclusive; and (3) subject to the approval of theshareholders of the Company, it was expected that the Final Dividend will be paid on oraround 24 May 2013 to the shareholders whose names appear in the register of members ofthe Company on 19 April 2013.
The Board would like to announce that as AGM would be rescheduled to be held onTuesday, 30 April 2013 (instead of 3 April 2013 as set out in the Announcement), theclosure periods of the register of members of the Company, the record date and paymentdate of the Final Dividend are rescheduled as follows:
the book closure period for the purpose of determining the entitlement to attend andvote at the AGM is rescheduled to Friday, 26 April 2013 to Tuesday, 30 April 2013,both days inclusive, during which period no transfer of shares of the Company will beeffected. As such, all transfers accompanied by the relevant share certificates must belodged with the Company’s branch share registrar and transfer office in Hong Kong,Tricor Investor Services Limited at 26/F Tesbury Centre, 28 Queen’s Road East, HongKong by 4: 30 p.m. on Thursday, 25 April 2013;
(ii) the book closure period for the purpose of determining the entitlement to the proposed
Final Dividend is rescheduled to Wednesday, 8 May 2013 to Friday, 10 May 2013, bothdays inclusive, during which period no transfer of shares of the Company will beeffected. As such, all transfers accompanied by the relevant share certificates must belodged with the Company’s branch share registrar and transfer office in Hong Kong,Tricor Investor Services Limited at 26/F Tesbury Centre, 28 Queen’s Road East, HongKong by 4: 30 p.m. on Tuesday, 7 May 2013; and
(iii) it is expected that the Final Dividend, if approved by the shareholders of the Company,
will be paid on or around 7 June 2013 to the shareholders whose names appear in theregister of members of the Company on 10 May 2013.
A notice to convene the AGM will be sent to all shareholders of the Company and will bepublished on the websites of the Company and the Stock Exchange in due course.
The People’s Republic of China, 28 February 2013
As at the date of this announcement, the Board comprises five executive directors, namelyMr. Rui Fubin, Mr. Rui Yiping, Ms. Xia Yafang, Mr. Jiang Yongwei and Mr. Hao Minghui;and four independent non-executive directors, namely Mr. He Zhisong Mr. Wu Changshun,Mr. Yang Rongkai and Mr. Poon Yick Pang Philip.
10217_revista club emas 13 30/12/11 08:21 Página 8 Espai compra verda FITXA COMPRA VERDA D’ELECTRICITAT 1. Categoria del producte 2.3 Avantatges del fet de tenir en compte criteris ambientals de compra d’e- lectricitat verda Contractació d’electricitat –Reducció de les emissions de gasos contaminants i gasos d’efecte hiverna-Des de no fa gaire, a l’Esta
Rethinking Innovation in Pharmaceutical R&D Health & Life Sciences The pharmaceutical industry is facing a challenge to be productive. One of thesolutions to this problem is for the industry to better harness innovation todeliver more and better drugs through the pipeline. But what is innovation and how can it deliver higher performance throughmore valuable drugs? Historically, p